Revvity, Inc. Common Stock RVTY 深 沪
已收盘 12-19 16:00:00 美东时间
96.24
-0.020
-0.02%
华盛通- 最 高97.10
- 今 开96.16
- 成交量 286.74万股
- 最 低 95.49
- 昨 收 96.26
- 总市值 113.56亿
- 52周最高 128.075
- 市盈率 静 39.96
- 换手率 2.43%
- 52周最低 81.29
- 委 比 17.01%
- 总股本 1.18亿
- 历史最高 202.04
- 量 比 1.99
- 振 幅 1.67%
- 历史最低 14.16
- 每 手 1
- 风险率 10.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
12-16 09:36
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
12-10 10:33
Goldman Sachs Initiates Coverage On Revvity with Neutral Rating, Announces Price Target of $105
Goldman Sachs analyst Evie Koslosky initiates coverage on Revvity (NYSE:RVTY) with a Neutral rating and announces Price Target of $105.
12-09 20:39
Revvity Agrees To Acquire ACD/Labs, Terms Undisclosed; Transaction Expected To Close Late In Q4 2025
Acquisition deepens Revvity Signals' presence in research informatics while furthering its ongoing expansion into development and manufacturing solutionsRevvity, Inc. (NYSE:RVTY), today announced it has entered into a
11-10 20:47
美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
10-29 09:25
Baird Maintains Outperform on Revvity, Raises Price Target to $123
Baird analyst Catherine Ramsey maintains Revvity (NYSE:RVTY) with a Outperform and raises the price target from $122 to $123.
10-28 20:20
Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025
Reviva Pharmaceuticals Holdings, Inc. announced that negative symptom data for brilaroxazine from the Phase 3 RECOVER trial and a long-term open-label extension trial in schizophrenia patients will be presented at the CNS Summit 2025 in Boston. The poster, titled "Brilaroxazine Treatment Effect on Negative Symptoms in Schizophrenia: RECOVER Trial in Acute and Stable Patients Over 1 Year," will be displayed on November 3rd and 4th. Abstract detail...
10-28 12:00
Revvity, Inc. Earnings Call: Mixed Sentiment and Strategic Growth
Revvity, Inc. (($RVTY)) has held its Q3 earnings call. Read on for the main hig...
10-28 08:06
Revvity Lifts Profit Outlook, Launches $1 Billion Buyback Plan
Revvity Inc. (NYSE: RVTY) announced mixed Q3 results, beating EPS but missing revenue estimates, leading to a decline in stock price.
10-27 21:34
Revvity Raises FY2025 Adj EPS Guidance from $4.85-$4.95 to $4.90-$5.00 vs $4.86 Est; Widens FY2025 Sales Guidance from $2.840B-$2.880B to $2.830B-$2.880B vs $2.849B Est
Revvity (NYSE:RVTY) raises FY2025 Adj EPS guidance from $4.85-$4.95 to $4.90-$5.00 vs $4.86 analyst estimate. Widens FY2025 sales outlook from $2.840 billion-$2.880 billion to $2.830 billion-$2.880 billion vs $2.849
10-27 18:01
公司简介
公司名称
|
Revvity, Inc.
|
行业分类
|
Medical Specialties
|
业务描述
|
Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.
|
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
12-16 09:36
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
12-10 10:33
Goldman Sachs Initiates Coverage On Revvity with Neutral Rating, Announces Price Target of $105
Goldman Sachs analyst Evie Koslosky initiates coverage on Revvity (NYSE:RVTY) with a Neutral rating and announces Price Target of $105.
12-09 20:39
Revvity Agrees To Acquire ACD/Labs, Terms Undisclosed; Transaction Expected To Close Late In Q4 2025
Acquisition deepens Revvity Signals' presence in research informatics while furthering its ongoing expansion into development and manufacturing solutionsRevvity, Inc. (NYSE:RVTY), today announced it has entered into a
11-10 20:47
美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
10-29 09:25
Baird Maintains Outperform on Revvity, Raises Price Target to $123
Baird analyst Catherine Ramsey maintains Revvity (NYSE:RVTY) with a Outperform and raises the price target from $122 to $123.
10-28 20:20
Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025
Reviva Pharmaceuticals Holdings, Inc. announced that negative symptom data for brilaroxazine from the Phase 3 RECOVER trial and a long-term open-label extension trial in schizophrenia patients will be presented at the CNS Summit 2025 in Boston. The poster, titled "Brilaroxazine Treatment Effect on Negative Symptoms in Schizophrenia: RECOVER Trial in Acute and Stable Patients Over 1 Year," will be displayed on November 3rd and 4th. Abstract detail...
10-28 12:00
Revvity, Inc. Earnings Call: Mixed Sentiment and Strategic Growth
Revvity, Inc. (($RVTY)) has held its Q3 earnings call. Read on for the main hig...
10-28 08:06
Revvity Lifts Profit Outlook, Launches $1 Billion Buyback Plan
Revvity Inc. (NYSE: RVTY) announced mixed Q3 results, beating EPS but missing revenue estimates, leading to a decline in stock price.
10-27 21:34
Revvity Raises FY2025 Adj EPS Guidance from $4.85-$4.95 to $4.90-$5.00 vs $4.86 Est; Widens FY2025 Sales Guidance from $2.840B-$2.880B to $2.830B-$2.880B vs $2.849B Est
Revvity (NYSE:RVTY) raises FY2025 Adj EPS guidance from $4.85-$4.95 to $4.90-$5.00 vs $4.86 analyst estimate. Widens FY2025 sales outlook from $2.840 billion-$2.880 billion to $2.830 billion-$2.880 billion vs $2.849
10-27 18:01
派息除权日
|
每股总股息
| 派息日期 |
2026-01-16
|
0.07
|
2026-02-06
|
2025-10-17
|
0.07
|
2025-11-07
|
2025-07-18
|
0.07
|
2025-08-08
|
2025-04-17
|
0.07
|
2025-05-09
|
2025-01-17
|
0.07
|
2025-02-07
|
2024-10-18
|
0.07
|
2024-11-08
|
2024-07-19
|
0.07
|
2024-08-09
|
2024-04-18
|
0.07
|
2024-05-10
|
2024-01-18
|
0.07
|
2024-02-09
|
2023-10-19
|
0.07
|
2023-11-10
|
2023-07-20
|
0.07
|
2023-08-11
|
2023-04-20
|
0.07
|
2023-05-12
|
2023-01-19
|
0.07
|
2023-02-10
|
2022-10-20
|
0.07
|
2022-11-11
|
2022-07-21
|
0.07
|
2022-08-12
|
2022-04-21
|
0.07
|
2022-05-13
|
2022-01-20
|
0.07
|
2022-02-11
|
2021-10-21
|
0.07
|
2021-11-12
|
2021-07-15
|
0.07
|
2021-08-06
|
2021-04-15
|
0.07
|
2021-05-07
|
2021-01-21
|
0.07
|
2021-02-12
|
2020-10-15
|
0.07
|
2020-11-06
|
2020-07-16
|
0.07
|
2020-08-07
|
2020-04-16
|
0.07
|
2020-05-08
|
2020-01-16
|
0.07
|
2020-02-07
|
2019-10-17
|
0.07
|
2019-11-08
|
2019-07-18
|
0.07
|
2019-08-09
|
2019-04-17
|
0.07
|
2019-05-10
|
2019-01-17
|
0.07
|
2019-02-08
|
2018-10-18
|
0.07
|
2018-11-09
|
2018-07-19
|
0.07
|
2018-08-10
|
2018-04-12
|
0.07
|
2018-05-10
|
2018-01-18
|
0.07
|
2018-02-09
|
2017-10-19
|
0.07
|
2017-11-10
|
2017-07-19
|
0.07
|
2017-08-10
|
2017-04-11
|
0.07
|
2017-05-10
|
2017-01-18
|
0.07
|
2017-02-10
|
2016-10-12
|
0.07
|
2016-11-10
|
2016-07-13
|
0.07
|
2016-08-10
|
2016-04-13
|
0.07
|
2016-05-10
|
2016-01-13
|
0.07
|
2016-02-10
|
2015-10-14
|
0.07
|
2015-11-10
|
2015-07-15
|
0.07
|
2015-08-10
|
2015-04-15
|
0.07
|
2015-05-11
|
2015-01-14
|
0.07
|
2015-02-06
|
2014-10-15
|
0.07
|
2014-11-07
|
2014-07-16
|
0.07
|
2014-08-08
|
2014-04-15
|
0.07
|
2014-05-09
|
2014-01-15
|
0.07
|
2014-02-07
|
2013-10-16
|
0.07
|
2013-11-08
|
2013-07-17
|
0.07
|
2013-08-09
|
2013-04-17
|
0.07
|
2013-05-10
|
2013-01-16
|
0.07
|
2013-02-08
|
2012-10-17
|
0.07
|
2012-11-09
|
2012-07-18
|
0.07
|
2012-08-10
|
2011-07-20
|
0.07
|
2011-08-12
|
2011-04-19
|
0.07
|
2011-05-13
|
2011-01-19
|
0.07
|
2011-02-11
|
2010-10-20
|
0.07
|
2010-11-12
|
2010-07-21
|
0.07
|
2010-08-13
|
2010-04-14
|
0.07
|
2010-05-07
|
2010-01-20
|
0.07
|
2010-02-12
|
2009-10-21
|
0.07
|
2009-11-13
|
2009-07-15
|
0.07
|
2009-08-07
|
2009-04-15
|
0.07
|
2009-05-08
|
2009-01-14
|
0.07
|
2009-02-06
|
2008-10-15
|
0.07
|
2008-11-07
|
2008-07-16
|
0.07
|
2008-08-08
|
2008-04-16
|
0.07
|
2008-05-09
|
2008-01-16
|
0.07
|
2008-02-08
|
2007-10-17
|
0.07
|
2007-11-09
|
2007-07-18
|
0.07
|
2007-08-10
|
2007-04-18
|
0.07
|
2007-05-11
|
2007-01-17
|
0.07
|
2007-02-09
|
2006-10-18
|
0.07
|
2006-11-10
|
2006-07-19
|
0.07
|
2006-08-11
|
2006-04-19
|
0.07
|
2006-05-12
|
2006-01-18
|
0.07
|
2006-02-10
|
2005-10-19
|
0.07
|
2005-11-11
|
2005-07-20
|
0.07
|
2005-08-12
|
2005-04-20
|
0.07
|
2005-05-13
|
2005-01-19
|
0.07
|
2005-02-11
|
2004-10-20
|
0.07
|
2004-11-12
|
2004-07-21
|
0.07
|
2004-08-13
|
2004-04-21
|
0.07
|
2004-05-14
|
2004-01-14
|
0.07
|
2004-02-05
|
2003-10-15
|
0.07
|
2003-11-07
|
2003-07-16
|
0.07
|
2003-08-08
|
2003-04-15
|
0.07
|
2003-05-09
|
2003-01-15
|
0.07
|
2003-02-07
|
2002-10-16
|
0.07
|
2002-11-08
|
2002-07-17
|
0.07
|
2002-08-09
|
2002-04-17
|
0.07
|
2002-05-10
|
2002-01-16
|
0.07
|
2002-02-09
|
2001-10-17
|
0.07
|
2001-11-09
|
2001-07-18
|
0.07
|
2001-08-10
|
2001-04-18
|
0.14
|
2001-05-10
|
2001-01-17
|
0.14
|
2001-02-09
|
2000-10-18
|
0.14
|
2000-11-10
|
2000-07-19
|
0.14
|
2000-08-10
|
2000-04-18
|
0.14
|
2000-05-10
|
2000-01-19
|
0.14
|
2000-02-10
|
1999-10-20
|
0.14
|
1999-11-10
|
1999-07-21
|
0.14
|
1999-08-10
|
1999-04-21
|
0.14
|
1999-05-10
|
1999-01-20
|
0.14
|
1999-02-10
|
1998-10-21
|
0.14
|
1998-11-10
|
1998-07-22
|
0.14
|
1998-08-10
|
1998-04-15
|
0.14
|
1998-05-08
|
1998-01-14
|
0.14
|
1998-02-06
|
1997-10-15
|
0.14
|
1997-11-10
|
1997-07-16
|
0.14
|
1997-08-08
|
1997-04-16
|
0.14
|
1997-05-09
|
1997-01-15
|
0.14
|
1997-02-10
|
1996-10-16
|
0.14
|
1996-11-08
|
1996-07-17
|
0.14
|
1996-08-09
|
1996-04-17
|
0.14
|
1996-05-10
|
1996-01-17
|
0.14
|
1996-02-09
|
1995-10-18
|
0.14
|
1995-11-10
|
1995-07-19
|
0.14
|
1995-08-10
|
1995-04-17
|
0.14
|
1995-05-10
|
1995-02-14
|
0.010
|
1995-02-14
|
1995-01-13
|
0.14
|
1995-02-10
|
1994-10-17
|
0.14
|
1994-11-10
|
1994-07-18
|
0.14
|
1994-08-10
|
1994-04-18
|
0.14
|
1994-05-10
|
1994-01-14
|
0.14
|
1994-02-10
|
1993-10-18
|
0.13
|
1993-11-10
|
1993-07-19
|
0.13
|
1993-08-10
|
1993-04-12
|
0.13
|
1993-05-07
|
1993-01-15
|
0.13
|
1993-02-10
|
1992-10-19
|
0.13
|
1992-11-10
|
1992-07-13
|
0.13
|
1992-08-07
|
1992-04-10
|
0.25
|
1992-05-08
|
1992-01-13
|
0.23
|
1992-02-07
|
1991-10-11
|
0.21
|
1991-11-08
|
1991-07-15
|
0.21
|
1991-08-09
|
1991-04-15
|
0.21
|
1991-05-10
|
1991-01-14
|
0.21
|
1991-02-08
|
1990-10-15
|
0.19
|
1990-11-09
|
1990-07-16
|
0.19
|
1990-08-10
|
1990-04-16
|
0.19
|
1990-05-10
|
1990-01-12
|
0.19
|
1990-02-09
|
1989-10-16
|
0.17
|
1989-11-10
|
1989-07-17
|
0.17
|
1989-08-10
|
1989-04-17
|
0.17
|
1989-05-10
|
1989-01-13
|
0.17
|
1989-02-10
|
1988-10-25
|
0.15
|
1988-11-10
|
1988-07-18
|
0.15
|
1988-08-10
|
1988-04-18
|
0.15
|
1988-05-10
|
1988-01-15
|
0.15
|
1988-02-10
|
1987-10-19
|
0.14
|
1987-11-10
|
1987-07-20
|
0.14
|
1987-08-07
|
1987-04-10
|
0.14
|
1987-05-08
|
1987-01-16
|
0.14
|
1987-02-10
|
1986-10-10
|
0.13
|
1986-11-07
|
1986-07-14
|
0.13
|
1986-08-08
|
1986-04-14
|
0.13
|
1986-05-09
|
1986-01-13
|
0.13
|
1986-02-07
|
1985-10-11
|
0.12
|
1985-11-08
|
1985-07-15
|
0.12
|
1985-08-09
|
1985-04-15
|
0.12
|
1985-05-10
|
1985-01-14
|
0.12
|
1985-02-08
|
1984-10-15
|
0.10
|
1984-11-09
|
1984-07-16
|
0.10
|
1984-08-10
|
1984-04-13
|
0.10
|
1984-05-10
|
1984-01-16
|
0.10
|
1984-02-10
|
1983-10-17
|
0.09
|
1983-11-10
|
1983-07-18
|
0.09
|
1983-08-10
|
1983-04-18
|
0.09
|
1983-05-10
|
1983-01-17
|
0.09
|
1983-02-10
|
1982-10-18
|
0.08
|
1982-11-10
|
1982-07-12
|
0.08
|
1982-08-02
|
1982-04-12
|
0.08
|
1982-05-03
|
1982-01-04
|
0.16
|
1982-01-08
|
1981-10-09
|
0.13
|
1981-11-02
|
1981-07-13
|
0.13
|
1981-08-03
|
1981-04-10
|
0.13
|
1981-05-01
|
1981-01-12
|
0.13
|
1981-02-02
|
1980-10-10
|
0.10
|
1980-11-03
|
1980-07-14
|
0.10
|
1980-08-01
|
1980-04-07
|
0.10
|
1980-05-01
|
1980-01-07
|
0.20
|
1980-02-01
|
1979-10-05
|
0.15
|
1979-11-01
|
1979-07-09
|
0.15
|
1979-08-01
|
1979-04-06
|
0.15
|
1979-05-01
|
1979-01-08
|
0.15
|
1979-02-01
|
1978-10-06
|
0.11
|
1978-11-01
|
1978-07-10
|
0.11
|
1978-08-01
|
1978-04-10
|
0.11
|
1978-05-01
|
1978-01-09
|
0.09
|
1978-02-01
|
1977-10-07
|
0.09
|
1977-11-01
|
1977-08-08
|
0.09
|
1977-09-01
|
1977-05-09
|
0.09
|
1977-06-01
|
